CSPC Pharmaceutical Gets China Nod for Clinical Trial of Cancer Drug

MT NewswiresDec 20 18:57

CSPC PHARMA (01093.HK) spent HKD 29.283 million on December 20 to repurchase 6.1 million shares.

On December 20, Geelonghui reported that CSPC PHARMA (01093.HK) announced that on December 20, 2024, it spent 29.283 million Hong Kong dollars to repurchase 6.1 million shares, with a repurchase price of 4.77-4.83 Hong Kong dollars per share.

Gelonghui FinanceDec 20 17:16

CSPC PHARMA (01093.HK): SYS 6005 (antibody-drug conjugate) has received approval for clinical trials.

On December 20, GELONGHUI reported that CSPC PHARMA (01093.HK) announced that the SYS 6005 (Antibody-Drug Conjugate) developed by the group has been approved by the National Medical Products Administration of China to conduct clinical trials in China. This product is a monoclonal antibody drug conjugate that can bind to specific receptors on the surface of tumors, enter the cells through endocytosis, and release toxins to kill tumor cells. This product is classified as a Category 1 Biological Product for therapeutic use, and the approved indication is for advanced tumors, which is expected to be applicable.

Gelonghui FinanceDec 20 16:59

CSPC PHARMA (01093): Semaglutide long-acting injection (SYH9017) has received approval for clinical trials.

CSPC PHARMA (01093) announced that the group has developed the GLP-1 receptor agonist semaglutide long-acting injection ...

Zhitong FinanceDec 20 16:51

Express News | CSPC Innovation Pharmaceutical: SYS6043 antibody-drug conjugate has received clinical trial approval.

BreakingsDec 20 15:55

Bank of America Merrill Lynch has lowered the Target Price for Shanghai Pharmaceuticals (01093.HK) to 4.6 yuan and raised the Target Price for INNOVENT BIO (01801.HK) to 56.4 yuan.

Merrill Lynch Securities released a Research Report stating that CSPC PHARMA (01093.HK) and BEIGENE (06160.HK) have reached a global exclusive licensing agreement for the group's novel methionine adenosyltransferase 2A (MAT2A) inhibitor SYH2039 and subsequent development. Taking into account the aforementioned collaboration and the recent bidding results of the tenth batch of national organization pharmaceutical centralized procurement, the revenue forecasts for CSPC PHARMA for 2024 to 2026 have been adjusted down by 0.8%, up by 1.7%, and down by 1.7%, respectively, while the earnings per share forecasts have been adjusted down by 0.9%, up by 10.5%, and down by 1.9%. Considering CSPC PHARMA's core product Enbrel.

AASTOCKSDec 20 09:44